Oleg V. Shevchenko

Oleg V. Shevchenko

Auto-generated profile, based on publicly available information

Oleg V. Shevchenko

Engelhardt Institute of Molecular Biology RAS, 32 Vavilova St., 119991 Moscow, Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LALiudmila Alexandrova
Liudmila Alexandrova
MJMaxim V. Jasko
Maxim V. Jasko
SNSergey D. Negrya
Sergey D. Negrya
PSPavel Solyev
Pavel Solyev
OSOleg V. Shevchenko
Oleg V. Shevchenko
Alexander ZhgunAlexander Zhgun
Alexander Zhgun

4 February 2022 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
LALiudmila Alexandrova
Liudmila Alexandrova
OSOleg V. Shevchenko
Oleg V. Shevchenko
MJMaxim V. Jasko
Maxim V. Jasko
PSPavel Solyev
Pavel Solyev
IKInna Karpenko
Inna Karpenko
Alexander ZhgunAlexander Zhgun
Alexander Zhgun
A set of 3′-modified N4-alkyl-5-methyl-2′-deoxycytidines has been synthesized and evaluated for biological activity. The replacement of the 3′-hydroxyl group with amino, aminoethyl and dialkylamino groups significantly enhances antifungal activity.

1 January 2021 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
SNS. D. Negrya
S. D. Negrya
MJM. V. Jasko
M. V. Jasko
DMDmitry A. Makarov
Dmitry A. Makarov
PSPavel Solyev
Pavel Solyev
IKInna Karpenko
Inna Karpenko
LALiudmila Alexandrova
Liudmila Alexandrova
Resistance developed to the majority of drugs used to treat infectious diseases warrants the design of new compounds effective against drug-resistant strains of pathogens. Recently, several groups of modified nucleosides have been synthesized and showed significant antibacterial activity in vitro, but their further studies were difficult to undertake because of their low solubility in aqueous solutions. Nevertheless, new compounds, well soluble in water-organic solutions, were synthesized and found to be more effective in inhibiting the growth of Gram-positive bacteria and mycobacteria. The water-soluble forms of modified nucleosides under study were assumed to be their depot forms. To check the assumption, the compounds were tested for hydrolysis in various media and their molecular docking was performed into the active center of the putative target, Mycobacterium tuberculosis flavin-dependent thymidylate synthase ThyX. Computer modelling showed that the water-soluble analogs do not act as ThyX inhibitors, supporting the assumption of their depot nature. The compounds were resistant to chemical hydrolysis but were hydrolyzed when incubated with porcine liver carboxylesterase, human serum, or Staphylococcus aureus 209P. The results demonstrate that the compounds are most likely depot forms of modified nucleosides.